Development of a vaccine for toxoplasmosis: Current status

Microbes and Infection

Volumn 5, Issue 5, 2003, Pages 457-462

  Bhopale, Girish M ^a  

^a Hindustan Antibiotics Ltd   (India)

Author keywords

Toxoplasmosis; Vaccine

Indexed keywords

CYTOKINE; DNA VACCINE; IMMUNOLOGICAL ADJUVANT; PARASITE ANTIGEN; TOXOPLASMA GONDII VACCINE;

DRUG EFFECT; HOST PARASITE INTERACTION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SHEEP; TOXOPLASMA GONDII; TOXOPLASMOSIS;

TOXOPLASMA GONDII;

EID: 0038665562     PISSN: 12864579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1286-4579(03)00048-0     Document Type: Review

References (59)

1. Jackson M.H., Hutchison W.M. Baker J.R., Muller R. Advances in Parasitology. 1989;55-86 Academic Press, London.
2. Bhopale G.M., Naik S.R., Bhave G.G., Naik S.S., Gogate A. Assessment of enzyme linked immunosorbent assay based diagnostic kits (Toxokit-G and Toxokit-M) for the detection of IgG and IgM antibodies to Toxoplasma gondii in human serum. Comp. Immun. Microbial. Infect. Dis. 20:1997;309-314.
3. Luft B.J., Remington J.S. Toxoplasmic encephalitis in AIDS. Clin. Infect. Dis. 15:1992;211-222.
4. Buxton D., Innes E.A. A commercial vaccine for ovine toxoplasmosis. Parasitology. 110:1995;S11-S16.
5. Ferguson D.J.P., Hutchison W.M. An ultrastructural study of the early development and tissue cyst formation of Toxoplasma gondii in the brains of mice. Parasitol. Res. 73:1987;483-491.
6. Kasper L.H. Identification of stage specific antigens of Toxoplasma gondii. Infect. Immun. 57:1989;668-672.
7. Woodison G., Smith J.E. Identification of the dominant cyst antigens of Toxoplasma gondii. Parasitology. 100:1990;389-392.
8. Lefrancois L., Fuller B., Huleatt J.W., Olson S., Puddington L. On the front lines, intraepithelial lymphocytes as primary effectors of intestinal immunity. Springer Semin. Immunopathol. 18:1997;463.
9. Lepage A.C., Buzoni-Gatel D., Bout D.T., Kasper L.H. Gut derived intraepithelial lymphocytes induce long term immunity against Toxoplasma gondii. J. Immunol. 161:1998;4902-4908.
10. Buzoni-Gatel D., Debabi H., Moreto M., Dimier-Bisson I.H. Intraepithelial lymphocytes traffic to the intestine and enhance resistance to Toxoplasma gondii infection. J. Immunol. 162:1999;5846-5852.
11. Gazzinelli R.T., Amichay D., Sharton-Kersten T., Grunwald E., Farber J.M., Sher A. Role of macrophage derived cytokines in the induction and regulation of cell mediated immunity to Toxoplasma gondii. Curr. Top. Immunol. 219:1996;127-140.
12. Sher A., Sousa C.R. Ignition of the type 1 response to intracellular infection by dendric cell derived interleukin-12. Eur. Cytokine Netw. 9:1998;65-68.
13. Sibley L.D., Adam S.L., Fukutomi Y. Tumor necrosis factor-alpha triggers antitoxoplasmal activity of IFN-gamma primed macrophages. J. Immunol. 147:1991;2340-2345.
14. Sher A., Oswald I.P., Hieny S., Gazzinelli R.T. Toxoplasma gondii induces a T independent IFN-gamma response in natural killer cells that requires both adherant accessory cells and tumor necrosis factor-alpha. J. Immunol. 150:1993;3982-3989.
15. Langermans J.A.M., Van Der Hulst M.E.B., Nibbering P.H., Hiemstra O.P.S., Fransen L., Van Furth R. INF-gamma induced L-arginine dependent toxoplasmastatic activity in murine peritoneal macrophages is mediated by endogenous tumor necrosis factor-alpha. J. Immunol. 148:1992;568-574.
16. Adams L.B., Hibbs J.B., Taintor R.R., Krahenbuhl J.L. Microbiostatic effect of murine activated macrophages for Toxoplasma gondii. Role for synthesis of inorganic nitrogen oxides from L-arginine. J. Immunol. 144:1990;2725-2729.
17. Jun C.D., Kim S.H., Soh C.T., Kang S.S., Chung H.T. Nitric oxide mediates the toxoplasmastatic activity of murine microglial cells in vitro. Immunol. Investig. 22:1993;487-501.
18. Scharton-Kersten T.M., Yap G., Magram J., Sher A. Inducible nitric oxide is essential for host control of persistent but not acute infection with the intracellular pathogen Toxoplasma gondii. J. Exp. M. 185:1997;1261-1273.
19. Pfefferkorn E.R. Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc. Natl. Acad. Sci. USA. 81:1984;908-912.
20. Fujigaki S., Saito K., Takemura M., Maekawa N., Yamada Y., Wada H., Seishima M. L-Tryptophan-L-Kynurenine pathway metabolism accelerated by Toxoplasma gondii infection is abolished in gamma interferon gene-deficient mice: cross regulation between inducible nitric oxide synthase and indoleamine-2,3-dioxygenase. Infect. Immun. 70:2002;779-786.
21. Gazzinelli R.T., Hakim F.T., Hieny S., Shearer G.M., Sher A. Synergistic role of CD4+ and CD8+ T lymphocytes in IFN-γ production and protective immunity induced by an attenuated Toxoplasma gondii vaccine. J. Immunol. 146:1991;286-292.
22. Khan I.A., Casciotti L. IL-15 prolongs the duration of CD8+ T cell mediated immunity in mice infected with a vaccine strain of Toxoplasma gondii. J. Immunol. 163:1999;4503-4509.
23. Subauste C.S., Koniaris A.H., Remington J.S. Murine CD8+ cytotoxic T lymphocytes lyse Toxoplasma gondii Infected cells. J. Immunol. 147:1991;3955-3959.
24. Montoya J.G., Lowe K.E., Clayberger C., Moody D., Do D., Remington J.S., Talib S., Subauste C.S. Human CD4+ and CD8+ T lymphocytes are both cytotoxic to Toxoplasma gondii infected cells. Infect. Immun. 64:1996;176-181.
25. Bohne W., Heesemann J., Gross U. Induction of bradyzoite specific Toxoplasma gondii antigens in gamma interferon treated mouse macrophages. Infect. Immun. 61:1993;1141-1145.
26. Bohne W., Heesemann J., Gross U. Reduced replication of Toxoplasma gondii is necessary for induction of bradyzoite-specific antigens. A possible role for nitric oxide in triggering stage conversion. Infect. Immun. 62:1994;1761-1767.
27. Soete M., Camus D., Dubremet Z. Experimental induction of bradyzoite-specific antigen expression and cyst formation by the RH strain of Toxoplasma gondii in vitro. Exp. Parasitol. 78:1994;361-370.
28. Weiss L.M., Laplace D., Takvorian P.M., Tanowitz H.B., Cali A., Wittner M. A cell culture system for study of the development of toxoplasma bradyzoites. J. Eukaryot. Microbiol. 42:1995;150-157.
29. Silva N.M., Tafuri W.L., Alvarez-Leite J.I., Mineo J.R., Gazzinelli R.T. Toxoplasma gondii: in vivo expression of BAG-5 and cyst formation is independent of TNFp55 receptor and inducible nitric oxide synthase functions. Microbes. Infect. 4:2002;261-271.
30. Brown C.R., Hunter C.A., Estes R.G., Beckmann E., Forman J., Devid C., Remington J.S., Mcleod R. Definitive identification of a gene that confers resistance against Toxoplasma cyst burden and encephalitis. Immunology. 85:1995;419-428.
31. Sibley L.D., Boothroyd J.C. Virulent strains of Toxoplasma gondii comprise a single clonal lineage. Nature. 359:1992;82-85.
32. Gazzinelli R.T., Eltoum I., Wynn T.A., Sher A. Acute cerebral toxoplasmosis is induced by in vivo neutralization of TNF-α and correlates with the down regulated expression of inducible nitric oxide synthase and other markers of macrophage activation. J. Immunol. 151:1993;3672-3681.
33. Hayashi S., Chan C.C., Gazzinelli R.T., Roberge G. Contribution of nitric oxide to the host parasite equilibrium in toxoplasmosis. J. Immunol. 156:1996;1476-1481.
34. Araujo F.G. Immunization against Toxoplasma gondii. Parasitol. Today. 10:1994;358-360.
35. Couvreur G., Sadak A., Fortier B., Dubremetz J.F. Surface antigens of Toxoplasma gondii. Parasitology. 97:1988;1-10.
36. Capron A., Dessaint J.P. Vaccination against parasitic diseases, some alternative concepts for the definition of protective antigens. Ann. Inst. Pasteur Immunol. 139:1988;109.
37. Cesbron M.F., Capran A. Excreted-secreted antigens of Toxoplasma gondii: their origin and role in the host parasite interaction. Res. Immunol. 144:(41):1993.
38. Cesbron Delauw M.F. Dense granule organelles of Toxoplasma gondii: their role in the host parasite relationship. Parasitol. Today. 10:1994;293.
39. Saavedra R., Becerril M.A., Dubeaux C., Lippens R., Vos M.D., Herion P., Bollen A. Epitopes recognized by human T lymphocytes in the RoP2 protein antigen of Toxoplasma gondii. Infect. Immun. 64:1996;3858-3862.
40. Bourguin I., Chardes T., Bout D. Oral immunization with Toxoplasma gondii antigens in association with cholera toxin induces enhanced protective and cell mediated immunity in C57BL/6 mice. Infect. Immun. 61:1993;2082-2088.
41. Wu H.Y., Russell M.W. Nasal lymphoid tissue, intranasal immunization and compartmentalization of the common mucosal immune system. Immunol. Res. 16:1997;187-201.
42. Debard N., Buzoni D., Bout-Gatel D. Intranasal immunization with SAG1 protein of Toxoplasma gondii in association with cholera toxin dramatically reduces development of cerebral cysts after oral infection. Infect. Immun. 64:1996;2158-2166.
43. Velge-Roussel F., Marcelo P., Lepage A.C., Buzoni-Gatel D., Bout D.T. Intranasal immunization with Toxoplasma gondii SAG1 induces protective cells into both NALT and GALT compartments. Infect. Immun. 68:2000;969-972.
44. Bonenfant C., Dimier-Poisson I., Velge-Roussel F., Buzoni-Gatel D., Del Giudice G., Rappuoli R., Bout D. Intranasal immunization with SAG1 nontoxic mutant heat labile enterotoxins protects mice against Toxoplasma gondii. Infect. immun. 69:2001;1605-1612.
45. Fermin Z., Bout D., Ricciardi-Castagnoli P., Hoebeke J. Salbutamol as an adjuvant for nasal vaccination. Vaccine. 17:1999;1936-1941.
46. Denkers E.Y., Gazzinelli R.T. Regulation and function of T cell mediated immunity during Toxoplasma gondii infection. Clin. Microbiol. Rev. 11:1998;569-588.
47. Lunden A., Lovgren K., Uggla A., Araujo F.G. Immune responses and resistance to Toxoplasma gondii in mice immunized with antigens of the parasite incorporated into immunostimulating complexes. Infect. Immun. 61:1993;2639-2643.
48. Bulow R., Bootroyd J.C. Protection of mice from fatal Toxoplasma gondii infection by immunization with P30 antigen in liposomes. J. Immunol. 147:1991;3496-3500.
49. Powers D.C., Manaing M.C., Hanscome P.J., Pietrobon P.J. Cytotoxic T lymphocyte responses to a liposome adjuvant influenza. A virus vaccine in the elderly. J. Infect. Dis. 172:1995;1103-1107.
50. Petersen E., Henrik V.N., Christiansen L., Spenter J. Immunization with E. coli produced recombinant T. gondii SAG1 with alum as adjuvant protect mice against lethal infection with Toxoplasma gondii. Vaccine. 16:1998;1283-1289.
51. Letscher Bru V., Villard O., Risse B., Zauke M., Klein J.P., Kien T.T. Protective effect of vaccination with a combination of recombinant surface antigen 1 and interleukin 12 against toxoplasmosis in mice. Infect. Immun. 66:1998;4503-4506.
52. Haumont M., Delhaye L., Garcia L., Jurado M., Mazza P., Daminet V., Verlant V., Bollen A., Biemans R., Jacquet A. Protective immunity against congenital toxoplasmosis with recombinant SAG1 protein in a Guinea pig model. Infect. Immun. 68:2000;4948-4953.
53. Chen X.G., Fung M.C., Ma X., Peng H.J., Shen S.M., Liu G.Z. Baculovirus expression of the major surface antigen of Toxoplasma gondii mice injected with the recombinant and the immune response of P30, Southeast Asian. J. Trop. Med. Public Health. 30:1999;42-46.
54. Nielsen H.V., Lauemoller S.L., Christiansen L., Buus S., Fomsgaard A., Petersen E. Complete protection against lethal Toxoplasma gondii infection in mice immunized with a plasmid encoding the SAG1 gene. Infect. Immun. 67:1999;6358-6363.
55. Angus C.W., Klivington-Evans D., Dubey J.P., Kovacs J.A. Immunization with a DNA plasmid encoding the SAG1 (P30) protein of Toxoplasma gondii is immunogenic and protective in rodents. J. Infec. Dis. 181:2000;317-324.
56. Desolme B., Marie-Noelle M., Buzoni-Gatel D., Bout D. Induction of protective immunity against toxoplasmosis in mice by DNA immunization with a plasmid encoding Toxoplasma gondii GRA4 gene. Vaccine. 18:2000;2512-2521.
57. Vercammen M., Scorza T., Huygen K., De Braekeleer J., Diet R., Jacobs D., Saman E., Verschueren H. DNA vaccination with genes encoding Toxoplasma gondii antigens GRA1, GRA7 and ROP2 induces partially protective immunity against lethal challenge in mice. Infect. Immun. 68:2000;38-45.
58. Supply P., Sutton P., Coughlan S.N., Bilo K., Saman E., Trees A.J., Delauw M.C., Locht C. Immunogenicity of recombinant BCG producing the GRA1 antigen from Toxoplasma gondii. Vaccine. 17:1999;705-714.
59. Saito S., Aosai F., Rikihisa N., Mun H.S., Norose K., Chen M., Kuroki T., Asano T., Ochiai T., Hata H., Ischinose M., Yano A. Establishment of gene vaccinated skin grafting against Toxoplasma gondii infection in mice. Vaccine. 19:2001;2172-2180.